Press Releases Shanghai Junshi Biosciences Co., Ltd. Deutsche Boerse AG

Equities

8SJ

CNE100003FF7

Delayed Deutsche Boerse AG Other stock markets 08:59:02 19/06/2024 BST			5-day change	1st Jan Change
1.41 ^EUR	+4.44%		-2.76%	-45.77%

06-18	Shanghai Junshi Biosciences Co., Ltd Announces Approval of the sNDA for Toripalimab for the 1st-Line Treatment of Small Cell Lung Cancer	CI
06-13	Junshi Biosciences' Cancer Drug Gets Registration Certificate from Chinese Regulator	MT

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Junshi Biosciences Announces Approval of the sNDA for Toripalimab for the 1st-Line Treatment of Small Cell Lung Cancer	06-18	GL
Junshi Biosciences Announces Approval of the sNDA for Toripalimab for the 1st-Line Treatment of Small Cell Lung Cancer	06-18	AQ
Junshi Biosciences Announces Phase 3 Study of Toripalimab Combined with Bevacizumab for the First-line Treatment of Advanced Hepatocellular Carcinoma Meets Primary Endpoint	06-12	GL
Junshi Biosciences Announces NDA Acceptance in Hong Kong for Toripalimab	04-25	GL
Junshi Biosciences Announces Approval of the sNDA for Toripalimab for the 1st-Line Treatment of Renal Cancer	04-07	AQ
Junshi Biosciences Announces Approval of the sNDA for Toripalimab for the 1st-Line Treatment of Renal Cancer	04-07	GL
Junshi Biosciences Announces 2023 Full Year Financial Results and Provides Corporate Updates	03-29	GL
Junshi Biosciences Announces Toripalimab’s NDA Accepted by the Singapore Health Sciences Authority	02-02	GL
Junshi Biosciences Announces JAMA Publication of Results from NEOTORCH, a Randomized Phase 3 Trial of Perioperative Toripalimab plus Chemotherapy for Patients with Resectable Non-Small Cell Lung Cancer	01-18	GL
Junshi Biosciences Announces Publication of Results from TORCHLIGHT, a Randomized Phase 3 Trial of Toripalimab for the Treatment of Metastatic or Recurrent Triple-negative Breast Cancer in Nature Medicine	01-10	GL
Junshi Biosciences Announces Approval of the Supplemental New Drug Application for Toripalimab as Perioperative Treatment for Resectable NSCLC Patients	01-02	AQ
Junshi Biosciences Announces Approval of the Supplemental New Drug Application for Toripalimab as Perioperative Treatment for Resectable NSCLC Patients	01-02	GL
Junshi Biosciences Announces New Chemical Entity Application for Toripalimab Accepted by Australia’s TGA	12-02	AQ
Junshi Biosciences Announces New Chemical Entity Application for Toripalimab Accepted by Australia’s TGA	12-02	GL
Coherus and Junshi Biosciences Announce Publication of Positive Final Overall Survival Results of JUPITER-02, a Phase 3 Trial Evaluating LOQTORZI as Treatment for Nasopharyngeal Carcinoma	11-29	AQ
Junshi Biosciences Announces Lancet Infectious Diseases Publication of Results from the 2nd Phase 3 Study of VV116 for Treating COVID-19	11-23	GL
FDA Approves LOQTORZI In All Lines Of Treatment For Recurrent Or Metastatic Nasopharyngeal Carcinoma	11-03	AQ
Coherus and Junshi Biosciences Announce FDA Approval of LOQTORZI in All Lines of Treatment for Recurrent or Metastatic Nasopharyngeal Carcinoma	30/10/23	AQ
Junshi Biosciences Presents 11 Clinical Trials of Toripalimab at the ESMO Congress 2023	27/10/23	GL
Junshi Biosciences Announces 2023 Interim Financial Results and Provides Corporate Updates	31/08/23	GL

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Shanghai Junshi Biosciences Co., Ltd. Deutsche Boerse AG

Equities

8SJ

CNE100003FF7

Press Releases

Filters